Moberg Pharma and Karo Healthcare have signed an exclusive agreement for the launch of MOB-015/Terclara in Europe, tapping into 19 markets.

Moberg Pharma's Phase 3 study for MOB-015 in North America has not met its primary endpoint, leading the company to refocus efforts in the EU market.

Moberg Pharma has secured an exclusive license with Karo Healthcare to commercialize MOB-015, Terclara in 19 major European markets. This collaboration enhances growth opportunities on a large scale.

Karo Healthcare has secured an exclusive licensing agreement with Moberg Pharma for the commercialization of MOB-015 across 19 European countries, enhancing its market presence with a new antifungal treatment.

Moberg Pharma AB and Allderma have commenced the launch of Terclara® (MOB-015) in Norway, aiming to replicate its Swedish success in the treatment of nail fungus.